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Abstract
Background: Fusion in addition to decompression has become the standard treatment for lumbar spinal stenosis
with degenerative spondylolisthesis (DS). The evidence for performing fusion among these patients is conflicting
and there is a need for further investigation through studies of high quality. The present protocol describes an
ongoing study with the primary aim of comparing the outcome between decompression alone and
decompression with instrumented fusion. The secondary aim is to investigate whether predictors can be used to
choose the best treatment for an individual. The trial, named the NORDSTEN-DS trial, is one of three studies in the
Norwegian Degenerative Spinal Stenosis (NORDSTEN) study.
Methods: The NORDSTEN-DS trial is a block-randomized, controlled, multicenter, non-inferiority study with two
parallel groups. The surgeons at the 15 participating hospitals decide whether a patient is eligible or not according
to the inclusion and exclusion criteria. Participating patients are randomized to either a midline preserving
decompression or a decompression followed by an instrumental fusion.
Primary endpoint is the percentage of patients with an improvement in Oswestry Disability Index version 2.0 of
more than 30% from baseline to 2-year follow-up. Secondary outcome measurements are the Zürich Claudication
Questionnaire, Numeric Rating Scale for back and leg pain, Euroqol 5 dimensions questionnaire, Global perceived
effect scale, complications and several radiological parameters. Analysis and interpretation of results will also be
conducted after 5 and 10 years.
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Conclusion: The NORDSTEN/DS trial has the potential to provide Level 1 evidence of whether decompression
alone should be advocated as the preferred method or not. Further on the study will investigate whether
predictors exist and if they can be used to make the appropriate choice for surgical treatment for this patient
group.
Trial registration: ClinicalTrials.gov Identifier: NCT02051374. First Posted: January 31, 2014. Last Update Posted:
February 14, 2018.
Keywords: Spinal stenosis, Degenerative spondylolisthesis, Randomized controlled trial, Decompression, Fusion,
Clinical outcomes, NORDSTEN
Background
Lumbar degenerative spondylolisthesis (LDS) is the for-
ward slip of one vertebra over another caused by degen-
eration and instability of facet joints, and degeneration
of ligaments and intervertebral discs [1]. Most patients
suffer from symptoms related to a concomitant spinal
stenosis, such as back pain, radiating pain to the lower ex-
tremities, and, typically, increased pain when walking up-
right and decreased pain when bending forward [2, 3].
Several meta-analyses and systematic reviews have
been published with the purpose of providing guidelines
on how to surgically treat patients with degenerative
spondylolisthesis. Based largely on a pseudorandomized
study from 1991 [4], they conclude that there is moder-
ate evidence for a tendency towards better outcome
when decompression is combined with fusion [3, 5–7].
A recently published randomized controlled trial (RCT)
has lent support to this evidence [8]. However, several
cohort studies [9–11] and another recently published
RCT [12], have introduced evidence against additional
fusion when operating for LDS.
The current evidence cannot support any definite ad-
vice on operation method [13–16]. Although challen-




The primary objective is to detect whether the
intervention-related difference in outcome between de-
compression alone (DA) and decompression with an add-
itional instrumented fusion (DF) 2 years after surgery, is
large enough to justify the use of instrumentation. Our hy-
pothesis is that DA is “as good as” DF for the treatment of
spinal stenosis with degenerative spondylolisthesis.
Secondary objectives
a. Health economic analysis: To compare the cost-
utility of the investigated treatments DA and DF [17].
b. Predictor analysis: To evaluate whether radiological
parameters and patient characteristics in the future
can be used by clinicians to choose between DA
and DF.
c. Long-time follow-up studies: The analyses per-
formed at 2-year follow-up will be repeated
at 5- and 10-year follow-up.
Trial design
The proposed trial is a 1:1 block-randomized, con-
trolled, multicenter, non-inferiority trial, with two par-
allel groups.
The study is one of three trials in the NORDSTEN
study, a Norwegian multicenter study on patients with
lumbar spinal stenosis [18].
Methods
The SPIRIT checklist [19] has been used as a template for
the present protocol. One exclusion criterion has been
detached from the original study protocol (Version 1.0)
received January 10, 2014 in Clinicaltrials.gov (Identifier:
NCT02051374), see ‘Amendment’.
The report of the trial will be based on an adapted
Consolidated Standards of Reporting Trials (CONSORT)
checklist for reporting non-inferiority trials [20].
Participants
The surgeons at the 15 participating hospitals (Table 1)
are following the inclusion and exclusion criteria to de-
cide whether a patient is eligible or not.
The patients are given verbal and written information
about the study and the alternative treatment options. If
willing to participate, the patients sign an informed con-
sent form. If a patient does not want to participate in the
study, he/she will not be included in the study and will re-
ceive normal care and be treated following the hospital’s
established procedures. Criteria for inclusion and exclu-
sion are given in Table 2.
All eligible patients are being registered, and the rea-
sons that some are not included are being documented
and interpreted. A CONSORT flow chart is illustrated
in Fig. 1.
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Interventions
Decompression alone
Posterior approach with decompression after microsurgical
principles will be performed, and the midline structures will
be preserved. The surgeons will either use a microscope or
magnifying glasses.
Decompression and instrumental fusion
Posterior approach with decompression will be performed,
followed by posterolateral pedicle screw fixation with or
without an additional cage. The surgeons will either use a
microscope or magnifying glasses.
Both groups will receive perioperative intravenous anti-
biotic prophylaxis. Postoperative care and mobilization
will follow each hospital’s normal practices and routines.
Outcomes
Patient reported outcome measures (PROMs) will be
collected preoperatively and at 3 months, 12 months, 2
years, 5 years and 10 years postoperatively. Primary end-
point is at 2-year follow-up. To evaluate the long-term
results (5- and 10-year follow-up) we will use the same
primary and secondary outcome measurements as at
2-year follow-up. The time schedule for collection of
data is shown in Table 3.
The primary outcome is the proportion of responders
assessed by the Oswestry Disability Index (ODI) V.2.0
[21, 22]. ODI scores range from 0 to 100, where 100 rep-
resent the greatest impairment. Based on former studies
[23, 24] and a presently not submitted study from The
Norwegian Registry for Spine Surgery (NORSpine), an
individual ODI improvement of 30% or more from base-
line to follow-up has been chosen as the cut-off for be-
ing a responder. Mean scores at follow-up and mean
change scores from baseline to follow-up for the ODI
scores will be secondary outcomes.
Other secondary outcome measurements are the mean
scores at follow-up, the mean changes from baseline to
follow-up and the responder rates assessed by the Zürich
Claudication Questionnaire [25] [ZCQ; which ranges
from 1 to 4 (worst disability)], and by the Numeric Rat-
ing Scale for back and leg pain (NRS; which ranges from
0 to 10 (worst pain imaginable)]. Cut-off values for being
a responder for ZCQ are defined by Tully et al. [25].
Based on data from NORSpine, the individual thresholds
Table 1 Recruiting hospitals
Oslo University Hospital, Orthopedic dept.
Akershus University Hospital, Orthopedic dept.
Bærum Hospital, Orthopedic dept.
Skien Hospital, Orthopedic dept.
Arendal Hospital, Orthopedic dept.
Gjøvik Hospital, Orthopedic dept.
Lillehammer Hospital, Orthopedic dept.
Stavanger University Hospital, Orthopedic dept. and dept. for
Neurosurgery
Haukeland University Hospital, Orthopedic dept. and dept. for
Neurosurgery
Kysthospitalet i Hagevik, Haukeland University Hospital, Orthopedic dept.
Ålesund Hospital, Orthopedic dept.
St. Olav University Hospital, dept. for Neurosurgery
University Hospital of Northern Norway, dept. for Neurosurgery
Kristiansand Hospital, Orthopedic dept.
Elverum Hospital, Orthopedic dept.
Table 2 Criteria for inclusion and exclusion for the NORDSTEN/DS trial
Inclusion criteria: Exclusion criteria:
To be eligible for the study the participants must: The participants will be excluded from the study if they:
Be over 18 years of age.
Understand Norwegian language, spoken and written.
Have a spondylolisthesis, with a slip > = 3 mm, verified on standing plain
x-rays in lateral view.
Have a spinal stenosis in the level of spondylolisthesis, shown on MRI, CT
scan or myelogram.
Have clinical symptoms of spinal stenosis as neurogenic claudication or
radiating pain into the lower limbs, not responding to at least 3 months
of qualified conservative treatment.
Be able to give informed consent and to respond to the questionnaires.
Are not willing to give written consent.
Are participating in another clinical trial that may interfere with this trial.
Are ASA- grade > 3.
Are older than 80 years.
Are not able to fully comply with the protocol, including treatment,
follow-up or study procedures (psychosocially, mentally and physically).
Have cauda equina syndrome (bowel or bladder dysfunction) or fixed
complete motor deficit.
Have a slip > = 3mm in more than one level.
Have an isthmic defect in pars interarticularis.
Have a fracture or former fusion of the thoracolumbal region.
Have had previous surgery in the level of spondylolisthesis.
Have a lumbosacral scoliosis of more than 20 degrees verified on AP-
view.
Have distinct symptoms in one or both legs due to other diseases, e.g.
polynevropathy, vascular claudication or osteoarthtritis.
Have radicular pain due to a MRI-verified foraminal stenosis in the slipped
level, with deformation of the nerve root because of a bony narrowing in
the vertical direction.
MRI Magnetic resonance imaging, CT Computed tomography, AP anterior- posterior, ASA American Society of Anesthesiologists
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for being a responder are defined as a 40% reduction in
the NRS leg pain and a 33% reduction in NRS back pain.
Additional secondary PROMs are the mean scores on
the Euroqol 5-D [26] (EQ-5D; which ranges from − 0.6 to
1, with higher scores indicating better quality of life) and
the scores on the Global Perceived Effect scale [27] (GPE;
a global assessment of patient-rated satisfaction with treat-
ment outcome, with the answers ‘completely recovered’,
‘much improved’, ‘slightly improved’, ‘unchanged’, ‘slightly
worse’, ‘much worse’ and ‘worse than ever’). For comparing
the failure rate between the groups, the proportion of pa-
tients replying ‘much worse’ or ‘worse than ever’ on the
GPE scale will be calculated and compared between the
groups.
In addition, we will compare the rates of complications
and adverse effects (Table 4), the volume of blood loss, the
use of blood transfusion perioperatively and postopera-
tively, the duration of the surgeries from the skin being
opened to when it is closed, and the length of hospital stays.
Any new surgery in the lumbosacral column from the time
of the index operation to follow-up will be recorded and
the reoperation rates will be compared. We will distinguish
between an operation at the same level as the primary oper-
ation and an operation in a new segment.
Fig. 1 Flow-chart for NORDSTEN-DS. Legend: Eligibility, randomization, treatment and follow-up
Austevoll et al. BMC Musculoskeletal Disorders            (2019) 20:7 Page 4 of 10
For descriptive interpretation, and for the predictor ana-
lyses, The Hopkins symptom check list (HSCL-25; a
self-reported questionnaire for assessment of psycho-
logical variables) [28], data concerning age, gender, educa-
tion, work, smoking habits, comorbidity, osteoporosis, the
American Society of Anesthesiologists (ASA) grade and
prior history of spinal surgery will be recorded preopera-
tively. For radiological evaluations we will assess the grade
of spinal stenosis [29], the foraminal stenosis [30], the
magnitude of the olisthesis [31], the segmental instability
[31], the orientation of the facet joint [32], the amount of
facet joint fluid [33], the degree of disc degeneration [34,
35], the disc height in the level of listhesis [36], the lumbar
lordosis [37] and the pelvic parameters (the sacral slope,
the pelvic tilt and the pelvic incidence) [37]. A CT scan
will be performed at the 2 year follow up for assessment of
fusion for the DF group [38]. The time schedule for radio-
logical examinations is given in Table 3. The radiological
evaluations will be performed by at least one spine sur-
geon and one radiologist.
Sample size
The sample size calculation for efficacy is based on the
hypothesis that the 2-year results for the decompression
alone group will be at least as good as those from the
fusion group when comparing the proportions of re-
sponders in each group. The sample size is computed by
using the Blackwelder methodology [39]. Based on data
from the Norwegian Spine Register, the proportion of
responders for the whole treatment group is expected to
be 0.70. Choosing a type 1 error = 0.05, power = 0.80 and
non-inferiority limit (δ) = 0.15 gives a sample size of 116.
Considering these assumptions and adding 10% for pos-
sible dropouts, a total of 128 patients are required in
each group.
Recruitment
To ensure a standardized system of enrollment, one or
two research coordinators at each hospital manage the
practical details regarding registration, collection and
further submission of patient data to the central coord-
inator at the Section for musculoskeletal research
(FORMI), Division of neuroscience, at Oslo University
Hospital.
Allocation
The computer generated 1:1 randomization is block-
permuted and center-stratified. After the patient has
signed the informed consent form, the randomization
is performed within the 6 weeks before treatment. The
computer generated randomization procedure is con-
cealed and administered by the central coordinator at
FORMI, and communicated by phone and by email to
the local research coordinator. The coordinator docu-
ments the result of the randomization in the patient’s
records and assigns the allocated surgical procedure to
the surgeon in charge. The randomization process can-
not be influenced by the patients, the investigators, the
surgeons or any other persons involved in the study.
Blinding
The treatment given is not blinded for the patients. For
analysis and testing of the efficacy variables, the statisti-
cian will be blinded for treatment adherence.
Data collection
The study coordinators are responsible for the collection
and administration of data at baseline and at 3-month
follow-up. Data from 12-month 2-year, 5-year and 10-year
follow-up is collected by the central coordinator at FORMI.
All data will be stored at the Faculty of Research support,
University of Oslo. The data will be inaccessible to the re-
search group until the first analysis at 2-year follow-up.
Statistical methods
The first analyses will be performed 2 years after surgery.
Long-term follow-up analyses will be performed at 5
and 10 years after surgery.
Table 3 Time schedule for collection of data for the NORDSTEN/DS trial
Before operation Hospital stay 3 months 12 months 2 years 5 years 10 years





PROMs x x x x x x
Operation data x
Data from hospital stay x
Complications, and reoperations x x x x x x
MRI Magnetic resonance imaging, CT Computed tomography, PROMs Patient reported outcome measures
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For the primary objective, the proportion of patients
with a reduction in ODI of 30% or more from baseline to
2-year follow-up (responder-rate) is defined as the primary
outcome [23, 40]. The null hypothesis (H0) is that the re-
sponder rate in the decompression alone group is inferior
the responder rate in the decompression and fusion group
with an amount of 0.15. H0 will be tested by forming a
95% confidence interval (CI) for the difference of propor-
tions, and H0 will be rejected if the upper limit of the con-
fidence interval (CI) is less than 0.15.
The alternative hypothesis is that the responder rate in
the DA group is non- inferior the responder rate in the
DF group (Fig. 2).
We have predefined the non- inferior margin to be 0.15
of 1.0, i.e., a 15 percentage difference in the responder rate
[41]. With this margin it will be necessary to treat 7 pa-
tients or more with fusion in addition to decompression
in order to prevent one responder. (Number needed to
treat = 1.0:0.15 = 6.67) [42].
The statistical analysis will be done according to
intention-to-treat principles (ITT). A sensitivity analysis
will be conducted where patient’s crossing over from one
treatment to another will receive the last score before
crossover. To recommend DA, both the ITT and the sen-
sitivity analysis are required to show non-inferiority.
Descriptive statistics, including measures of centrality
and variability, will be used to describe the baseline
characteristics of the two treatment groups.
The difference in the proportions of responders (the
primary outcome) will be estimated with the Newcombe
hybrid score CI [43]. Categorical secondary outcomes
will be analyzed with Fisher mid-P tests and Newcombe
hybrid score intervals. The GPE responses will be ana-
lyzed with a proportional odds logistic regression
model. We will use linear mixed models to estimate the
difference between the treatment groups for the con-
tinuous secondary outcomes (all follow-up measure-
ments from inclusion to 2-year follow-up will be
included). Because most change from baseline is ex-
pected to occur the first three months, the time devel-
opment in the linear mixed models will be modelled as
piecewise linear, with a knot at 3 months. The models
will include fixed effects for treatment group, time, and
treatment group x time interaction. A random intercept
will be used, and – if possible – a random effect for
treatment group.
Missing data
For the primary outcome, the primary analysis will be a
complete case analysis. If there are patients with missing
data in the primary outcome, sensitivity analyses with
different imputation scenarios will be performed. The
scenarios include all DA patients (with missing data) are
responders and none of the DF patients (with missing
data) are responders, and vice versa; all DA and all DF
patients are responders; all DA and all DF patients are
non-responders. Missing data for the continuous sec-
ondary outcomes will be handled by the linear mixed
Table 4 Complications and side effects registered during the
hospital stay
Perioperative Postoperative
Dural tear Liquor leakage
Nerve root lesion Superficial infection
Operated on the wrong side Neurological deterioration
Operated on the wrong level Hematoma requiring reoperation
Amount of bleeding Use of blood transfusion
Cardiopulmonary complications Deep infection







Fig. 2 Test for non-inferiority. Legend: The figure shows two alternative results for the primary outcome. DA and DF indicate the proportion of
responders in the decompression alone group and decompression plus instrumented fusion group, respectively. The bars indicate the absolute
difference in proportion of responders (DF-DA) with 95% confidence interval (CI) limits. Non-inferiority for DA is shown if the upper limit of the
95% CI for the difference is less than 15%
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models, which include all patients with a measurement
at at least one time point.
Complete case analyses will be performed on the cat-
egorical secondary outcomes. A significance level of 5%
will be used throughout.
Analyses of secondary objectives
Predictor analysis The predictor analysis will be per-
formed by use of a pragmatic model-building approach
of Hosmer et.al [44]. This method is advocated when
risk factor modelling is of interests and not just predic-
tion [45]. Patients treated with decompression alone and
decompression with fusion will be analyzed in separate
cohorts. For each cohort the following purposefully se-
lected baseline variables will be tested for their associ-
ation to the primary outcome variable ‘responder’: 1)
Patient age; 2) Gender; 3) Comorbidity (ASA group); 4)
Body Mass Index; 5) Smoking; 6) ODI score; 7) NRS
back pain score; 8) NRS leg pain score; 9) Hopkins
symptom check list (HSCL-25); 10) The magnitude of
olisthesis; 11) Segmental instability; 12) Presence of fo-
raminal stenosis; 13) Orientation of the facet joint; 14)
Amount of facet joint fluid; 15) Disc degeneration; 16)
Disc height in the level of olisthesis; 17) Lumbal lordosis;
18) Pelvic incidence.
From a univariate screening, variables with P < 0.25
will be included in the multivariate analyses. Since age
and gender will be of interests for clinicians when
searching for the best choice of treatment, these vari-
ables will be included throughout the multivariate ana-
lysis. In the second step, the iterative process, covariates
are removed if they are non- significant predictors at the
0.1 alpha level and not a confounder. Confounding is de-
fined as a change in any remaining covariate more than
15% when removing a covariate from the model. The co-
variates will be deleted in descending rang according to
the p-value. After deleting and refitting, the model will
contain only significant covariates and confounders. In
the next step, the covariates not selected from the uni-
variate analysis one by one will be tested for their contri-
butions in the presence of variables from the retained
model. If significant at alpha level 0.15 they are included
for further fitting of the multivariate model. Finally the
model is iteratively reduced as before, but only variables
additionally added will be excluded. From the final best
fitted model for each treatment group, predicted prob-
abilities of being a responder will be estimated for each
combination of the covariates. The risk estimates will be
used for building matrixes for an individual’s overall risk
for being a responder following surgery. Previously, risk
matrix models for predicting probability given a set of
established predictors has been constructed for other
conditions [46, 47].
Cost-utility analysis Cost-utility will be analyzed as the
difference in costs between the two treatment groups di-
vided by their difference in Quality adjusted life years
(QALYs) gained [48, 49]. QALYs will be estimated by com-
bining EQ-5D index and time, calculating the area under
the curve using the trapezoidal method. The results will
be presented as an incremental cost-effectiveness ratio
(ICER), meaning the cost for each unit of effect (QALY)
gained from decompression alone instead of decompres-
sion with instrumented fusion. The presentation will be
done from a health provider perspective based on data
from two-year follow-up.
Clinical monitoring of the trial
The trial is monitored following the Helsinki Declaration,
The International Conference on Harmonisation Guide-
line for Good Clinical Practice (ICH GCP) [50]. An inde-
pendent monitor affiliated with Møre and Romsdal Health
Trust, without influence on the scientific work, will be re-
sponsible for the monitoring. Due to the non-regulated
ICH GCP guideline for this trial (not including drug inter-
vention) the risk and safety will be safeguarded at the
same level as data quality. All informed consent forms will
be checked and all registrations of serious events will be
monitored. According to the monitoring plan selected
variables will be checked. All hospitals will be visited regu-
larly. Adapted versions of the ‘Investigator’s Site File (ISF)’
and the ‘Trial Master File (TMF)’ will be checked for es-
sential documents during the trial. Queries and deviations
will be recorded and reported, and the coordinator at the
responsible hospital will have two months to send a writ-
ten report with the required corrections to the monitor.
Interim analysis and stopping rules
Due to ethical considerations in agreement with the
Norwegian Committee for Medical and Health Research
Ethics Midt, an interim analysis for safety will be per-
formed when 75 patients in each group have completed
the 12-month follow- up. If one of the proposed stop
criteria is fulfilled the study will be terminated:
1. The proportion of patients needing reoperation due
to any condition in the operated level(s) is
statistically significantly higher in one of the groups.
2. The proportion of responders in the DF group,
assessed by the primary outcome measure, is higher
than in the DA group by an amount of 0.20.
The interim analysis will be conducted by an independ-
ent statistician blinded for treatment adherence. Only data
on reoperations and on the primary outcome measure
(ODI) will be available to the statistician. The statistician
will inform the steering committee, via the central coord-
inator, whether the study can be continued or not. Further
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information about the analysis will not be disclosed and
will not be available to anyone until the main analysis at
2-year follow-up.
Ethics and dissemination
The protocol has been approved by the Norwegian
Committee for Medical and Health Research Ethics Midt
(2013/366).
Storage of data is approved by the Norwegian Data
Inspectorate. Written informed consent is obtained from
the patients. The project is in accordance with the Helsinki
Declaration.
None of the principal investigators have any financial
or other competing conflicts of interest.
Trial results will be communicated at national and inter-
national conferences and published in well-recognized
journals.
Discussion
The rationale, design and method for this prospective
randomized clinical multi-center trial on patients with
LDS are presented in the current protocol.
We have chosen a non-inferiority design in order to
investigate whether clinical outcomes for decompression
alone are not worse than decompression with fusion by
more than an acceptable amount. Superiority for decom-
pression alone is not considered to be necessary; it would
be an additional benefit [20].
The present study will be the largest powered study
comparing decompression alone and decompression with
instrumented fusion in a randomized setting. It is de-
signed and powered to provide Level 1 evidence for
whether decompression alone can be advocated as the
preferred method for surgical treatment of DS or not. We
also aim to investigate whether patients can be assigned to
the most appropriate surgical method. Finally, results at 5-
and 10-year follow-up will provide high level evidence for
long-time results for the two methods.
We anticipate enclosing the inclusion by the end of
2017.
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